Study on 24-hour Na excretion effect of sustained ARB Azilsartan and its effect on blood pressure
Not Applicable
Recruiting
- Conditions
- Hypertensive patients with complication of chronic kidney disease
- Registration Number
- JPRN-UMIN000032240
- Lead Sponsor
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients who are receiving ARB, ACE inhibitors, renin inhibitors within 2 weeks (2) Patients falling under the contraindications of Azir Sultan (3) Patients with severe hypertension (4) Patients with CKDstage 5 or higher (5) patients with insulin treatment (6) Patients who are pregnant or nursing (7) Patients with severe liver dysfunction (8) Patients who are judged inappropriate for the research subject by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Azilsartan's 24-hour sodium excretion effects in hypertensive CKD patients?
How does Azilsartan's sustained sodium excretion compare to standard ARB therapies in managing CKD-related hypertension?
Which biomarkers correlate with enhanced blood pressure control and sodium excretion in Azilsartan-treated CKD patients?
What adverse events are associated with Azilsartan's prolonged sodium excretion in CKD populations and how are they managed?
Are there synergistic effects when combining Azilsartan with other RAS inhibitors in treating CKD-associated hypertension?